Bioscience Today

11/11/2026

Major boost for UK innovation: £46m of new backing has been announced for the next generation of science-led startups and spinouts.

This funding aims to help early-stage, research-driven ventures bridge the gap between breakthrough science and real-world impact – a critical phase where many promising ideas struggle to secure support.

From university spinouts to cutting-edge life sciences and deep tech ventures, this kind of targeted backing can play a key role in turning lab discoveries into scalable solutions, jobs and growth across the UK.

Read the full story here: https://www.biosciencetoday.co.uk/46m-backing-for-next-generation-of-innovative-uk-science-led-startups/

The British Business Bank will commit up to £46m to the Zinc Science-for-Impact Fund. The Bank has agreed to commit up to £46 million to Zinc Capital Management’s second institutional fund, the Science-for-Impact Fund, to accelerate the development of innovative UK deep tech startups tackling cr...

11/11/2026

Combatting Blood Brain Barrier breakdown in age-related neurological diseases https://www.biosciencetoday.co.uk/combatting-blood-brain-barrier-breakdown-in-age-related-neurological-diseases/

Amsbio is a premier supplier of high-quality heparan sulfate (HS) monoclonal antibodies for use in brain and neurodegenerative research. In a recent published study** from Stanford University, these antibodies have been used to reveal a key role for endothelial glycocalyx degradation in aging and ne...

11/11/2026

Could the metals accumulating inside tumour cells help explain why some lung cancers resist chemotherapy? Research involving Durham University and Pleco Therapeutics suggests combinations of metals may reduce treatment effectiveness - and that this resistance could potentially be reversed.

Read more: https://www.biosciencetoday.co.uk/heavy-metals-may-be-helping-lung-cancer-resist-chemotherapy/

Researchers at Durham University, working with Pleco Therapeutics (Netherlands), have uncovered a surprising new reason why some lung cancers stop responding to chemotherapy: the combined action of several different metals inside tumour cells. While metals such as copper, zinc and iron are already k...

10/11/2026

Touch-free review, or a signature on the algorithm? https://www.biosciencetoday.co.uk/touch-free-review-or-a-signature-on-the-algorithm/

Part 1 of 2: What AI-enabled MLR means for the medical signatory By Shazad Jafri, ABPI Medical Signatory and Founder, SignAffairs, and Vivanti Europe This summer, two developments arrived within a month of each other. They deserve to be read together. In June, Veeva acquired Copli and launched what....

09/11/2026

Beyond the signature: Building AI assurance into MLR workflows https://www.biosciencetoday.co.uk/beyond-the-signature-building-ai-assurance-into-mlr-workflows/

Part 2/2: If AI does more of the review, what does the human need to see? By Marina Hickson, Vivanti Europe, and Shazad Jafri, ABPI Medical Signatory and Founder, SignAffairs AI is becoming capable of handling increasingly complex medical, legal and regulatory (MLR) review activities. Beyond checkin...

09/11/2026

Could monitoring hormone levels over time reveal a cause of high blood pressure that conventional tests miss? Research using the U-RHYTHM wearable sampling technology identified previously hidden hormone spikes in patients with primary aldosteronism, potentially informing earlier diagnosis of this often-overlooked condition.

Read more: https://www.biosciencetoday.co.uk/hidden-hormone-spikes-may-reveal-high-blood-pressure-condition/

A common but often overlooked cause of high blood pressure may be hiding in plain sight – and data from a pioneering wearable device could hold the key to its earlier diagnosis. A study published in the journal Science Translational Medicine concerns a condition called primary aldosteronism – a ...

06/11/2026

A £50 million government-backed fund is opening new opportunities for life sciences innovation in the West Midlands. The Local Innovation Partnerships Fund aims to help eligible organisations develop and scale near-to-market products and services, with collaboration between industry, academia and the public sector central to eligibility.

Read more: https://www.biosciencetoday.co.uk/50m-funding-available-for-west-midlands-life-sciences/

Life sciences firms in the West Midlands can apply for a share of £50m in funding from the Local Innovation Partnerships Fund to help develop and scale their near to market products and services. Expressions of interest (EOI) can be submitted for the research and development funding support allocat...

04/11/2026

Two UK biotech companies, Flip Therapeutics and Nascent Therapeutics, have each secured £500,000 in funding, alongside strategic support from Medicines Discovery Catapult. Their approaches target chronic inflammatory and age-related diseases, including psoriasis and Parkinson's.

Read more: https://www.biosciencetoday.co.uk/medicines-discovery-catapult-invests-in-uk-biotech-pioneers-developing-novel-treatments-for-chronic-diseases/

04/11/2026

Maternal Sepsis: The Immunological Complexity Behind Delayed Recognition https://www.biosciencetoday.co.uk/maternal-sepsis-the-immunological-complexity-behind-delayed-recognition/

Sepsis has long remained one of the leading causes of avoidable mortality worldwide, contributing to an estimated 1 in 5 deaths (1). Maternal sepsis, defined as life-threatening organ dysfunction resulting from infection during pregnancy, childbirth, post-abortion, or the postpartum period, presents...